Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Liraglutide, a GLP ... basal insulin, continues to be a cornerstone of advanced diabetes management. In the future, these medications are expected to be improved through the use of combination ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Compared with currently available insulin ... mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination ...

The two incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide potentiate nutrient-dependent insulin secretion following meal ingestion. Metabolic ...

The report – which can be viewed here – highlights the following new medicines: 1) Novo Nordisk's Awiqli (LAI 287; insulin ... fixed-dose combination of an amylin analogue and GLP-1 agonist ...

A new study has found a combination of an SGLT-2 inhibitor drug ... of people globally living with diabetes will grow to at least 1.3 billion by 2050. “Diabetes has been considered as an ...